Looking for a biopharma job in Boston? Check out the BioSpace list of nine companies hiring life sciences professionals like ...
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company ...
Kailera will launch a global Phase 2 study of ribupatide this year, while Hengrui will push the asset into Phase 3 in China.
The agency flagged several violations at a compounding pharmacy owned by Hims & Hers, including “infestation by rodents, ...
This webinar provides a clear-eyed assessment of current hiring conditions across biopharma, exploring which roles and skills ...
The FDA recommended that REGENXBIO run a new study, treat more patients and include a placebo arm to support a resubmission ...
AstraZeneca will push the pill, elecoglipron, into a comprehensive late-stage program that will test the drug as a ...
Novo Nordisk has sued Hims for allegedly violating patents protecting semaglutide, seeking potentially “hundreds of millions” ...
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
The newly public Evommune shared data showing that EVO301, an IL-18 targeting protein, cleared symptoms comparably to Regeneron and Sanofi’s mega-blockbuster in a mid-stage atopic dermatitis clinical ...
As the field grows rapidly, companies are luring people from other nuclear industries and tapping the expanding educational ...
The deal gets Lilly access to Orna’s in vivo CAR T technology. The biotech’s lead asset, which has yet to start clinical ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results